COVID-19 Pneumonia
Conditions
Brief summary
This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm Nitazoxanide, Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. Two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. Initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. The procedures are to be approved by the institutional ethical committee.
Detailed description
This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm Nitazoxanide, Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. Two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. Initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. The procedures are to be approved by the institutional ethical committee.
Interventions
DRUGIvermectin,ribavirin ,nitazoxanide and zinc
oral intake of the 3 drugs ivermectin ,ribavirin and nitazoxanide plus zinc
Sponsors
Mansoura University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥18 years * Laboratory-confirmed SARS-CoV- 2 infection * Hospitalized patients * need reservoir mask for oxygen support * need HFNC for oxygen support
Exclusion criteria
* Mechanical ventilations for oxygen support * Inability to take oral medications * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stabilization of oxygen | 28 days | at room air more than 90% |
| In-hospital and 28-day mortality | 28 day | — |
Secondary
| Measure | Time frame |
|---|---|
| Negative conversion of SARS-CoV- 2 by Day 28 | 28 day |
| Time to clinical improvement | 28 day |
Countries
Egypt
Contacts
Primary ContactHatem elalfy, MD
Outcome results
None listed